Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ADALIMUMAB Cause Clostridium difficile infection? 1,502 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 1,502 reports of Clostridium difficile infection have been filed in association with ADALIMUMAB (YUSIMRY). This represents 0.3% of all adverse event reports for ADALIMUMAB.

1,502
Reports of Clostridium difficile infection with ADALIMUMAB
0.3%
of all ADALIMUMAB reports
33
Deaths
977
Hospitalizations

How Dangerous Is Clostridium difficile infection From ADALIMUMAB?

Of the 1,502 reports, 33 (2.2%) resulted in death, 977 (65.0%) required hospitalization, and 21 (1.4%) were considered life-threatening.

Is Clostridium difficile infection Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ADALIMUMAB. However, 1,502 reports have been filed with the FAERS database.

What Other Side Effects Does ADALIMUMAB Cause?

Drug ineffective (71,926) Pain (37,514) Arthralgia (35,592) Rheumatoid arthritis (29,817) Fatigue (29,420) Injection site pain (28,679) Headache (19,891) Nausea (19,299) Rash (18,690) Pain in extremity (18,319)

What Other Drugs Cause Clostridium difficile infection?

INFLIXIMAB (1,419) VEDOLIZUMAB (1,130) LENALIDOMIDE (814) VANCOMYCIN (743) METRONIDAZOLE (619) PREDNISONE (618) METHOTREXATE (588) RITUXIMAB (532) CIPROFLOXACIN (508) CYCLOPHOSPHAMIDE (504)

Which ADALIMUMAB Alternatives Have Lower Clostridium difficile infection Risk?

ADALIMUMAB vs ADALIMUMAB-AACF ADALIMUMAB vs ADALIMUMAB-AATY ADALIMUMAB vs ADALIMUMAB-ADAZ ADALIMUMAB vs ADALIMUMAB-ADBM ADALIMUMAB vs ADALIMUMAB-AFZB

Related Pages

ADALIMUMAB Full Profile All Clostridium difficile infection Reports All Drugs Causing Clostridium difficile infection ADALIMUMAB Demographics